ASCO 2023 | STARTAR: AR inhibition + ADT + apalutamide + RT + docetaxel for salvage in PSA recurrent PC after RP

Andrew J. Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, the primary analysis of the Phase II STARTAR (NCT03311555) salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). The primary endpoint was 36-month progression-free survival (PFS). Results from the trial demonstrated that the 36-month PFS rate was 72%, with durable remissions beyond historical controls. Most patients completed the planned treatment, achieved undetectable PSA levels, and experienced manageable adverse events. This study suggests that intensifying systemic treatments in the non-metastatic hormone-sensitive but high-risk salvage setting may be feasible and effective in reducing cancer progression. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.